KR102709096B1 - 종양 성장 억제 물질 및 방법 - Google Patents

종양 성장 억제 물질 및 방법 Download PDF

Info

Publication number
KR102709096B1
KR102709096B1 KR1020207012608A KR20207012608A KR102709096B1 KR 102709096 B1 KR102709096 B1 KR 102709096B1 KR 1020207012608 A KR1020207012608 A KR 1020207012608A KR 20207012608 A KR20207012608 A KR 20207012608A KR 102709096 B1 KR102709096 B1 KR 102709096B1
Authority
KR
South Korea
Prior art keywords
cancer
composition
delete delete
cell
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207012608A
Other languages
English (en)
Korean (ko)
Other versions
KR20200060492A (ko
Inventor
사다시반 비디아사가르
레슈 구프타
스티븐 가토
Original Assignee
유니버시티 오브 플로리다 리서치 파운데이션, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 플로리다 리서치 파운데이션, 인크. filed Critical 유니버시티 오브 플로리다 리서치 파운데이션, 인크.
Publication of KR20200060492A publication Critical patent/KR20200060492A/ko
Application granted granted Critical
Publication of KR102709096B1 publication Critical patent/KR102709096B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207012608A 2017-10-02 2018-10-02 종양 성장 억제 물질 및 방법 Active KR102709096B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566787P 2017-10-02 2017-10-02
US62/566,787 2017-10-02
PCT/US2018/054015 WO2019070750A1 (en) 2017-10-02 2018-10-02 MATERIALS AND METHODS FOR INHIBITING TUMOR GROWTH

Publications (2)

Publication Number Publication Date
KR20200060492A KR20200060492A (ko) 2020-05-29
KR102709096B1 true KR102709096B1 (ko) 2024-09-23

Family

ID=64049688

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207012608A Active KR102709096B1 (ko) 2017-10-02 2018-10-02 종양 성장 억제 물질 및 방법

Country Status (7)

Country Link
US (1) US12109191B2 (https=)
EP (1) EP3691628A1 (https=)
JP (2) JP7352901B2 (https=)
KR (1) KR102709096B1 (https=)
CN (2) CN118078810A (https=)
CA (1) CA3078335A1 (https=)
WO (1) WO2019070750A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
EP3796922B1 (en) * 2018-05-22 2026-03-18 Seleq Oy Pharmaceutical compositions comprising a seleno amino acid compound for use in combination with another agent for the treatment of liver or pancreas cancer
IT201800006725A1 (it) 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
IT201900002109A1 (it) 2019-02-13 2020-08-13 Professional Dietetics Spa Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale
IT202000000454A1 (it) * 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro
IT202000000442A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
JP2023531872A (ja) * 2020-05-29 2023-07-26 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド 急性呼吸窮迫症候群、喘息、又はアレルギー性鼻炎を治療するための製剤及び方法
CN115192564B (zh) * 2022-05-23 2023-11-17 四川大学华西医院 一种苯丙氨酸衍生物、药物组合物及其在肿瘤治疗中的应用
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003021A2 (en) 2013-07-01 2015-01-08 The Trustees Of Princeton University Dietary supplements and composition for treating cancer
WO2017053328A1 (en) 2015-09-21 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nutritional treatment for cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPH01301619A (ja) * 1988-05-30 1989-12-05 Otsuka Pharmaceut Factory Inc 癌用アミノ酸製剤
JPH0368514A (ja) * 1989-08-09 1991-03-25 Morishita Pharmaceut Co Ltd 癌用アミノ酸製剤
WO1993006934A1 (en) 1991-09-30 1993-04-15 Devtech Labs, Inc. Electrostatic separation of plastic materials
KR0172193B1 (ko) * 1991-10-07 1999-02-01 오오쓰까 아끼히꼬 암 치료용 경장제제
US5658895A (en) 1991-10-07 1997-08-19 Otsuka Pharmaceutical Factory, Inc. Anticancer enteral feeding composition
JP3429327B2 (ja) * 1992-07-20 2003-07-22 味の素ファルマ株式会社 癌用アミノ酸輸液剤
JPH06256184A (ja) * 1993-03-05 1994-09-13 Morishita Roussel Kk 癌患者用アミノ酸製剤
JP4683881B2 (ja) 2003-08-27 2011-05-18 有限会社アーク技研 抗腫瘍活性剤
US20050176807A1 (en) * 2004-02-09 2005-08-11 Friesen Kim G. Composition and method for use in cartilage affecting conditions
AU2005308538A1 (en) * 2004-08-09 2006-06-01 Enrique Melendez Hevia Glycine as a diet supplement for the treatment of health problems that result from underlying metabolic disorders
KR101758424B1 (ko) 2010-09-24 2017-07-14 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 위장 기능을 증진시키기 위한 물질 및 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003021A2 (en) 2013-07-01 2015-01-08 The Trustees Of Princeton University Dietary supplements and composition for treating cancer
WO2017053328A1 (en) 2015-09-21 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nutritional treatment for cancer

Also Published As

Publication number Publication date
JP2023171755A (ja) 2023-12-05
WO2019070750A1 (en) 2019-04-11
CA3078335A1 (en) 2019-04-11
JP2020536096A (ja) 2020-12-10
KR20200060492A (ko) 2020-05-29
CN111417391B (zh) 2024-06-18
CN111417391A (zh) 2020-07-14
JP7352901B2 (ja) 2023-09-29
EP3691628A1 (en) 2020-08-12
US12109191B2 (en) 2024-10-08
CN118078810A (zh) 2024-05-28
US20200323820A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
KR102709096B1 (ko) 종양 성장 억제 물질 및 방법
US10717735B2 (en) Solid forms of a compound for modulating kinases
JP2022020003A (ja) がんを治療するための四環式キノロン類似体の併用療法
US20120010229A1 (en) Therapeutic regimens for hedgehog-associated cancers
CN110062621A (zh) 氨基酸组合物及其用途
WO2010033771A2 (en) Modulators of hsp70/dnak function and methods of use thereof
US10882863B2 (en) Compounds for reducing c-Myc in c-Myc overexpressing cancers background
AU2018242612A1 (en) Dose and regimen for an HDM2-p53 interaction inhibitor in hematological tumors
US20230277522A9 (en) Methods for treating vascular malformations
JP2024504260A (ja) セリンおよびグリシンの制限の調節およびそれらの制限に対する感受性化のための方法
WO2019175799A2 (en) Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds
CN104918630A (zh) 抗药性癌细胞的抑制
AU2020279003A1 (en) Oxathiazin compounds for inhibiting GAPDH
US11583509B2 (en) Compound for treating cancer and diabetes
TWI891650B (zh) 治療血管畸形之方法
US20220289686A1 (en) Compositions of nrf2 inhibiting agents and methods of use thereof
JP2026509320A (ja) がんを治療するための併用療法
US11992478B2 (en) Methods of using androgen receptor inhibitors as cancer therapeutics
WO2025056747A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
Al-Odat Selective Small Molecule Targeting of MCL-1 in Multiple Myeloma
WO2016111957A1 (en) Chloroquinoline triazole compounds, composition and uses
JP2026508996A (ja) 癌を処置するためのｔｅａｄ及びｈｅｒ２阻害剤の組み合わせ

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200429

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211005

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231031

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240731

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240919

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240919

End annual number: 3

Start annual number: 1

PG1601 Publication of registration